Cargando…
Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely for patients to fully benefit. Gastric acid antisecretory drugs and particularly proton pum...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024146/ https://www.ncbi.nlm.nih.gov/pubmed/36764092 http://dx.doi.org/10.1016/j.esmoop.2023.100880 |
_version_ | 1784909041362796544 |
---|---|
author | Raoul, J.L. Moreau-Bachelard, C. Gilabert, M. Edeline, J. Frénel, J.S. |
author_facet | Raoul, J.L. Moreau-Bachelard, C. Gilabert, M. Edeline, J. Frénel, J.S. |
author_sort | Raoul, J.L. |
collection | PubMed |
description | New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely for patients to fully benefit. Gastric acid antisecretory drugs and particularly proton pump inhibitors (PPIs) revolutionized the treatment of gastroduodenal ulcers and severe gastroesophageal reflux, but are frequently overused for symptomatic treatment of epigastric pain or heartburn. Long-term acid suppression may alter the efficacy of many anticancer drugs, such as tyrosine kinase inhibitors (TKIs), cyclin-dependent kinase (CDK) 4/6 inhibitors and immune checkpoint inhibitors (ICIs), by either decreasing gastric acid secretion and thus drug absorption, or by modifying the gut microbiome that modulates the response to ICIs. Oncologists thus need to pay particular attention to the concomitant use of PPIs and anticancer drugs. These interactions translate into major clinical impacts, with demonstrated loss of efficacy for some TKIs (erlotinib, gefitinib, pazopanib), and conflicting results with many other oral drugs, including capecitabine and CDK 4/6 inhibitors. Furthermore, the profound changes in the gut microbiome due to using PPIs have shown that the benefit of using ICIs may be suppressed in patients treated with PPIs. As the use of PPIs is not essential, we must apply the precautionary principle. The first sentence of a recent Comment in Nature was “Every day, millions of people are taking medications that will not help them”. We fear that every day millions of cancer patients are taking medications that harm them. While this may well be only association and not causation, there is enough to make us pause until we reach a clear answer. All these data should encourage medical oncologists to refrain from prescribing PPIs, explaining to patients the risks of interaction in order to prevent inappropriate prescription by another physician. |
format | Online Article Text |
id | pubmed-10024146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100241462023-03-19 Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure Raoul, J.L. Moreau-Bachelard, C. Gilabert, M. Edeline, J. Frénel, J.S. ESMO Open Review New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely for patients to fully benefit. Gastric acid antisecretory drugs and particularly proton pump inhibitors (PPIs) revolutionized the treatment of gastroduodenal ulcers and severe gastroesophageal reflux, but are frequently overused for symptomatic treatment of epigastric pain or heartburn. Long-term acid suppression may alter the efficacy of many anticancer drugs, such as tyrosine kinase inhibitors (TKIs), cyclin-dependent kinase (CDK) 4/6 inhibitors and immune checkpoint inhibitors (ICIs), by either decreasing gastric acid secretion and thus drug absorption, or by modifying the gut microbiome that modulates the response to ICIs. Oncologists thus need to pay particular attention to the concomitant use of PPIs and anticancer drugs. These interactions translate into major clinical impacts, with demonstrated loss of efficacy for some TKIs (erlotinib, gefitinib, pazopanib), and conflicting results with many other oral drugs, including capecitabine and CDK 4/6 inhibitors. Furthermore, the profound changes in the gut microbiome due to using PPIs have shown that the benefit of using ICIs may be suppressed in patients treated with PPIs. As the use of PPIs is not essential, we must apply the precautionary principle. The first sentence of a recent Comment in Nature was “Every day, millions of people are taking medications that will not help them”. We fear that every day millions of cancer patients are taking medications that harm them. While this may well be only association and not causation, there is enough to make us pause until we reach a clear answer. All these data should encourage medical oncologists to refrain from prescribing PPIs, explaining to patients the risks of interaction in order to prevent inappropriate prescription by another physician. Elsevier 2023-02-08 /pmc/articles/PMC10024146/ /pubmed/36764092 http://dx.doi.org/10.1016/j.esmoop.2023.100880 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Raoul, J.L. Moreau-Bachelard, C. Gilabert, M. Edeline, J. Frénel, J.S. Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure |
title | Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure |
title_full | Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure |
title_fullStr | Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure |
title_full_unstemmed | Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure |
title_short | Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure |
title_sort | drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024146/ https://www.ncbi.nlm.nih.gov/pubmed/36764092 http://dx.doi.org/10.1016/j.esmoop.2023.100880 |
work_keys_str_mv | AT raouljl drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure AT moreaubachelardc drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure AT gilabertm drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure AT edelinej drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure AT freneljs drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure |